Description
Since at least 1963, obviousness-type double patenting rejections, their implications and responses thereto have been relatively straightforward. This straightforward understanding has been upset by the recent Cellect and Allergan cases. This presenation and discussion will focus on the inferences of these cases, and potential thoughts going forward. This meeting will be held both in person and virtually. A confirmation email with the Zoom link will be sent out prior to the meeting. Please reach out to Allison Silva at asilva@nhbar.org with any questions.